A Phase 2 interventional study of Doxil in Autoimmune Thrombocytopenic Purpura, sponsored by Hematology and Oncology Specialists. Status unknown at 1 site in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Hematology and Oncology Specialists · Phase 2, Interventional, and Treatment
This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.
263 studies on the registry are indexed under Purpura; 27 are open to participants now.
This study's enrollment of 10 is below the median of 50 across 171 interventional studies indexed under Purpura.
Browse Purpura studies →This is the only study on the registry with Hematology and Oncology Specialists as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
the primary outcome would be a platelet response, with a return of platelet count to normal
This study is status unknown, as verified in Apr 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.